2024-02-11 11:03:24
Significant advances in the Treatment of non-Hodgkin’s lymphoma (DLBCL) offer a glimmer of hope for patients facing this potentially fatal disease. The NHS in the United Kingdom has approved two new drugs, l’epcoritamab and loncastuximab tesirine, thus providing a new treatment option for those whose cancer has not responded to other treatments.
DLBCL, an aggressive form of blood cancer, key approximately 5,500 Britons every yearwith some relatively low survival rates. The new drugs have been hailed as a lifeline for patients, providing new insights where options were limited.
L’epcoritamab, marketed under the name Tepkinly, acts like a bispecific antibody, specifically targeting cancer cells and stimulating the immune system to fight the disease. Trials have shown promising results, with 39% of patients declared cancer-free after only ten months of treatment.
The the effect of loncastuximab, as for him, acts by administering a chemotherapy targeted to cancer cells, with encouraging results also reported in early clinical trials.
Dr. Dima El-Sharkawi, consultant haematologist at the Royal Marsden NHS Foundation Trust in London, points out that these drugs offer a glimmer of hope for patients who have not responded to other treatments. The successes seen in early trials are encouraging, providing a new perspective for patients facing this devastating disease.
Patients like Alexander Gudmestad, who was diagnosed with DLBCL in 2020, have had their lives transformed by these new medications. After following several unsuccessful treatments, Alexander started taking epcoritamab last October, with positive results reported during a recent scan. These advances in the treatment of DLBCL represent a significant step forward in the fight against this complex and deadly disease.
1707652921
#England #hopes #patients #aggressive #blood #cancer #drugs